AVADEL PHARMACEUTICALS PLC
AVDLAvadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FT218 | Phase 3 | Narcolepsy | - | - |
Frequently asked questions
What is in AVADEL PHARMACEUTICALS PLC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in AVADEL PHARMACEUTICALS PLC's (AVDL) pipeline across Phase 3. Its lead program is FT218 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AVADEL PHARMACEUTICALS PLC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for AVADEL PHARMACEUTICALS PLC (AVDL) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AVDL biotech catalysts?→
Add AVDL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AVADEL PHARMACEUTICALS PLC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.